Sanofi’s $9.1 Billion Power Move—Is This the Start of an Immunology Revolution?

Unknown Apr 02, 2026 750 Views

French pharmaceutical giant Sanofi has announced the acquisition of Blueprint Medicines, a US-based biopharma company specializing in rare immunological diseases, for $9.1 billion. The deal strengthens Sanofi’s immunology pipeline, adding Ayvakit/Ayvakyt (avapritinib)—the only approve...